Can Dendreon Be Saved?

Dendreon's press releases over the past year are seemingly filled with nothing but bad news. Investors suffered another gut punch today, as shares plummeted 23% amid declining Provenge sales -- but also in the face of a significant operational shake-up that should let the company more easily break even. Watch health-care editor and analyst David Williamson break down what these events mean for investors.

Many investors are attracted to biotechs like Dendreon, since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

David Williamson owns shares of Johnson & Johnson and Dendreon, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 31, 2012, at 11:20 PM, fhadidi wrote:

    your suck ......

  • Report this Comment On August 01, 2012, at 2:27 PM, calsu wrote:

    I think that Denderon met their estimate of single digit growth. They did not meet the higher estimates provided by the journalist and hedge funds who carry the water for the short interest. 25% short interest in DNDN almost insures a downward plunge especially when conspirators such as Motely provide their disparaging comments. I hope that this company finally succeeds and they provide an alternative to chemical castration. It is good that other biotechs are learning from DNDN's work. Perhaps, inspite of Motely's efforts to destroy the company, the company will make available medical services to members of

    Motely

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1966437, ~/Articles/ArticleHandler.aspx, 11/28/2014 7:28:47 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement